Herbert H. Loong - Concepedia

Author

Herbert H. Loong

Also Known As

Florence Siu Ting Mok, H H F Loong, H H Loong, H H-F Loong, H Ho Fung Loong, H. H. F. Loong, H. H. Loong, H. Loong, H.H-f. Loong, H.H. Loong

313

Publications

8.4K

Citations

H-Index

Concepts

All Affiliations

Chinese University of Hong Kong Prince of Wales Hospital The University of Texas MD Anderson Cancer Center Institut Gustave Roussy Memorial Sloan Kettering Cancer Center

About

Herbert H. Loong is an author at Chinese University of Hong Kong specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	29	1.9K
2	Health Sciences	11	11	1.1K
3	Cell Biology	2	2	69
4	Public Health	1	1	38
5	Biomedical Engineering	1	1	469

Herbert H. Loong

Publications

6.7K

Citations

H-Index

Page 1

	Year	Citations
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares, The Lancet Oncology	2019	1.7K
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, New England Journal of Medicine	2020	810
Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers Vincent Wai‐Sun Wong, Stephen L. Chan, Frankie Mo, Journal of Clinical Oncology	2010	497
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat, The Lancet Oncology Radiation MedicineRadiation TherapyMedicineAdvanced Soft-tissue SarcomaRadiopharmaceutical Therapy	2019	469
Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial Anthony T.�C. Chan, Edwin P. Hui, Roger K.C. Ngan, Journal of Clinical Oncology Plasma Epstein-barr VirusMedicineImmunologyNasopharyngeal CancerPathology	2018	240
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion–Positive NSCLC Caicun Zhou, Benjamin Solomon, Herbert H. Loong, New England Journal of Medicine	2023	186
Selpercatinib in Patients With <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial Alexander Drilon, Vivek Subbiah, Oliver Gautschi, Journal of Clinical Oncology	2022	185
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma Mrinal M. Gounder, Alona Zer, William D. Tap, Journal of Clinical Oncology	2016	161
Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response Winnie Yeo, Stephen L. Chan, Frankie Mo, BMC Cancer	2015	133
Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial Vivek Subbiah, Justin F. Gainor, Geoffrey R. Oxnard, Clinical Cancer Research	2021	133

Page 1